Aurobindo Pharma share price has zoomed 4% and is presently trading at Rs 1,570.6.
Meanwhile, the BSE HEALTHCARE index is at 44,231.6 (up 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are FDC (up 8.4%) and HIKAL CHEMIC (up 4.4%).
SUVEN PHARMACEUTICALS (down 1.0%) and Natco Pharma (down 0.4%) are among the top losers today.
Over the last one year, Aurobindo Pharma has moved up from Rs 867.7 to Rs 1,570.6, registering a gain of Rs 702.9 (up 81.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,436.8 to 44,231.6, registering a gain of 55.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 128.3%), SUVEN PHARMACEUTICALS (up 127.6%) and GRANULES INDIA (up 118.8%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,779.6 (up 0.3%).
The top gainers among the BSE Sensex today are Tata Steel (up 1.9%) and MUNDRA PORT & SEZ (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,010.0 (up 0.4%). Tata Steel and Shriram Transport are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,127.1 to 81,779.6, registering a gain of 14,652.5 points (up 21.8%).
Aurobindo Pharma net profit grew 60.6% YoY to Rs 9,196 million for the quarter ended June 2024, compared to a profit of Rs 5,725 million a year ago. Net sales rose 10.5% to Rs 75,670 million during the period as against Rs 68,505 million in April-June 2023.
For the year ended March 2024, Aurobindo Pharma reported 64.4% increase in net profit to Rs 31,690 million compared to net profit of Rs 19,277 million during FY23. Revenue of the company grew 16.7% to Rs 290,019 million during FY24.
The current Price to earnings ratio of Aurobindo Pharma, based on rolling 12 month earnings, stands at 26.0.
Equitymaster requests your view! Post a comment on "Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!